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Human Idiopathic Membranous Nephropathy -A Mystery Solved?
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Just over 50 years ago, the late David Jones 1 iden tified (using the periodic acid-Schiff and meth enamine silver stains) the unique glomerular pathologic features of membranous nephropathy, thus distinguishing it from other causes of "ne phrotic glomerulonephritis." Subsequent immuno fluorescence and electronmicroscopical studies established that membranous nephropathy was also characterized by striking granular aggrega tions of IgG and electrondense deposits along the outer (or subepithelial) aspect of the glomer ular basement membrane. These glomerular IgG deposits were initially believed to represent an accumulation of immune complexes arising from the circulation, as is found with glomerulonephri tis in a rabbit model (chronic serum sickness). In 1959, Heymann et al. 2 described a rat mod el of membranous nephropathy, similar to the dis ease in humans, induced by active immunization with crude kidney extracts in complete Freund's adjuvant. Initially, this model was also believed to be due to deposition of immune complexes from the circulation. Subsequently, however, Van Damme et al. 3 and Couser et al. 4 demonstrated that a circulating antibody reacted with and bound to the primary antigenic target located on podo cytes -the visceral epithelial cells of the glo merulus -indicating that the disease was caused by the in situ formation of immune complexes. Others soon showed that additional antigens, nor mally extrinsic to the kidney, that were "planted" artificially in the glomeruli (the glomerular base ment membrane or podocyte) through biophys ical attraction to the capillary wall could provoke an identical lesion (Fig. 1) .
Both the target antigen and the autoantibody operative in Heymann's model were eventually characterized; thus, all of Witebsky's postulates 5 were fulfilled, defining the autoimmune nature of the disease in the rat model.
However, translation of the pathogenesis of the rat model to idiopathic membranous nephrop athy in humans proved difficult. The target an tigen responsible for Heymann's model appeared to be absent in human kidneys. 6 Diligent search es for the autoantibody against the "Heymann" antigen (now known to be megalin [glycoprotein 330]) were unrewarding. 6 Thus, the true patho genesis of human idiopathic membranous ne phropathy remained unresolved. Now, this longlasting mystery may well have been solved by Beck et al., 7 as reported in this issue of the Journal. Autoantibodies against an antigen normally expressed on the podocyte cell membrane in humans, the Mtype phospholipase A 2 receptor (PLA 2 R), appear to circulate and bind to a conformational epitope (or epitopes) present on PLA 2 R, producing in situ deposits character istic of those associated with membranous ne phropathy. These autoantibodies are large ly, but not exclusively, immunoglobulins of the IgG4 sub class, similar to those seen in most instances of idiopathic membranous nephropathy in patients. Other renal diseases and secondary forms of membranous nephropathy (such as lupus mem branous nephropathy) do not appear to involve such autoantibodies.
Beck et al. also present preliminary indications of an association between the clinical features of the disease (proteinuria and the nephrotic syn drome) and the presence and titer of the circu lating autoantibodies. If the disease can be trans ferred to nonhuman primates that express the PLA 2 R antigen on podocytes or if the subepithe lial deposits can be shown to recur rapidly in a kidney transplanted from a normal donor to a Sorting out this apparent conun drum will require the sharing of serum samples between laboratories studying membranous ne phropathy and independent confirmation in an other population of patients with idiopathic membranous nephropathy, with the use of both antiPLA 2 R and anti-neutral endopeptidase as says simultaneously. In addition, an older obser vation regarding a putative role for anti-αenolase autoantibodies found in Japanese patients with membranous nephropathy should be reexam ined. 10 The variety of autoantibodies seen in pa tients with idiopathic membranous nephropathy may represent the phenomenon of epitope spread ing, as observed in other chronic autoimmune diseases. 11 Serial examination of serum samples obtained and stored years before the apparent onset and diagnosis of membranous nephropa thy should be enlightening in testing this hy pothesis. 12 Better understanding of the potential autolo gous or environmental triggers of autoantibody production in patients with membranous nephrop athy may uncover possible targets for preventing the disease. The binding of the autoantibody to its relevant antigen on the podocyte cell surface may be sufficient to initiate the disease process. However, much data from experimental and clin ical investigations suggest that in situ activation of the complement cascade and generation of the membraneattack complex of complement in the capillary wall play important roles in the ensuing glomerular permeability defects that lead to pro teinuria. This poses a dilemma, since the IgG4 subclass is known to activate complement only poorly, if at all, yet the dominant autoantibodies in the circulation and in the deposits are of the IgG4 subclass. 7 Perhaps the concomitant produc tion of IgG1 or IgG2 autoantibodies is required for the full expression of the abnormal glomer ular permeability.
Future investigations will undoubtedly yield answers to these tantalizing questions. Mean while, it is likely that the seminal observations of Beck et al. will have a profound effect on how clinicians approach the diagnosis and treatment of membranous nephropathy. Assays for anti PLA 2 R autoantibody (and perhaps anti-neutral endopeptidase as well) may permit the noninva sive diagnosis of membranous nephropathy as well as provide a convenient way to follow the activity of the disease in response to treatment. Five decades after its initial recognition, mem branous nephropathy is now entering an exciting and dynamic new era.
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Production of nephrotic syndrome in rats by Freund's adjuvant and rat kidney suspensions. The hypothesis that inhibition of the renin-angio tensin system may be effective in preventing dia betic nephropathy was based on a large body of evidence. 1 Positive findings from studies in ani mal models and subsequent clinical trials fos tered enthusiastic hope that systematic use of agents blocking the renin-angiotensin system in the management of diabetic nephropathy would reduce the risk of endstage renal disease. 2-4 Out of such studies was born a concept that gained wide acceptance: inhibition of the renin-angio tensin system in patients with diabetes is benefi cial with regard to both early and advanced stages of nephropathy. As an extension, studies were initiated to investigate the mechanism and role of inhibition of the renin-angiotensin system in other complications of diabetes, such as retinop athy and neuropathy. 5, 6 The study by Mauer et al. 7 in this issue of the Journal (ClinicalTrials.gov number, NCT00143949)
Diabetes Complications and the Renin-Angiotensin System
